Breast Cancer Hormone and Targeted Therapy: Treatment, Biomarkers and Side Effects

Hormone therapy and targeted therapy are often mentioned together, but they work in different ways. Hormone therapy, also called endocrine therapy, lowers estrogen levels or blocks their effects on hormone receptor-positive breast cancer cells. Targeted therapy works differently, using medicines that interfere with specific proteins or molecular pathways that help cancer cells grow.

The right treatment depends on the cancer’s hormone receptors, HER2 status, other biomarkers and stage, making accurate testing an important first step. In early and locally advanced breast cancer, treatment may aim to eliminate the cancer and reduce the risk of recurrence. In metastatic disease, treatment generally aims to control the cancer, prolong survival and maintain quality of life.

If you are considering a second opinion or treatment abroad, you can also explore treatment in Germany through the TIG team, which helps international patients coordinate specialist consultations, treatment planning, hospital arrangements and follow-up care alongside their treating doctors.

Breast Cancer Biomarkers and Treatment Choices

Different tumors need different medicines. These markers guide the decision:

• ER and PR: estrogen and progesterone receptors. If your tumor has them, it is called hormone receptor positive.
• HER2: a protein that can drive cancer growth. HER2 positive cancers may be treated with separate HER2 medicines.
• BRCA1 and BRCA2: genes that repair DNA. An inherited (germline) harmful variant can make some patients eligible for PARP inhibitors.
• ESR1: a change that can appear in the tumor during hormone therapy for advanced cancer.
• PIK3CA, AKT1 and PTEN: gene changes that can guide certain treatments in advanced hormone receptor positive, HER2 negative cancer.

A pathologist tests the tumor for ER, PR and HER2. Germline changes, such as BRCA, are inherited and found by blood or saliva tests. Somatic changes, such as ESR1 or PIK3CA, develop in the tumor and show up in tumor tissue or blood.

Your treatment path at a glance; details vary by patient.

Hormone Therapy for Early and Advanced Breast Cancer

Hormone therapy is used for hormone receptor-positive breast cancer. After surgery, it lowers the risk of recurrence. In some postmenopausal patients who cannot have surgery or chemotherapy immediately, it may be used first to control or shrink the tumor. In advanced disease, it can be used alone or combined with targeted therapy.

The main options are tamoxifen, aromatase inhibitors and ovarian function suppression, which reduces ovarian hormone production. Aromatase inhibitors are used after menopause or before menopause with ovarian suppression. Tamoxifen can be used before or after menopause. In advanced disease, medicines such as fulvestrant, which targets estrogen receptors, may also be used.

Targeted Medicines Matched to Tumor Biology

• CDK4/6 inhibitors(abemaciclib, ribociclib, palbociclib) slow cancer-cell division and are commonly combined with hormone therapy. Abemaciclib and ribociclib may be used in selected high-risk early breast cancers, with different eligibility criteria. Palbociclib has not shown a recurrence benefit in early disease.
• PARP inhibitors(olaparib, talazoparib) are used in selected HER2-negative cancers with an inherited harmful BRCA1 or BRCA2 variant. Olaparib is used in certain high-risk early and advanced cancers, while talazoparib is used for selected locally advanced or metastatic cancers.
• PI3K and AKT pathway medicinestarget molecular changes that can drive cancer growth. Options include alpelisib for PIK3CA-mutated cancer, capivasertib for PIK3CA, AKT1 or PTEN alterations, and inavolisib for certain PIK3CA-mutated, endocrine-resistant advanced cancers.
• ESR1-targeted medicinesmay be used when an ESR1 mutation develops in advanced hormone receptor-positive, HER2-negative cancer. Options include elacestrant, imlunestrant and vepdegestrant, with some treatments combined with a CDK4/6 inhibitor in specific settings.

How Long Does Treatment Last?

In early breast cancer, hormone therapy usually lasts at least 5 years, and some people continue longer depending on recurrence risk and tolerance. In advanced disease, treatment generally continues while it controls the cancer and you tolerate it. Your team may change it if the cancer grows or side effects are too hard to manage.

Side Effects and the Tests That Track Them

The side effects you may experience depend on the treatment you receive, so monitoring can range from managing everyday symptoms to checking blood counts, liver function, blood sugar and heart rhythm.

Hot Flashes, Joint Pain and Bone Loss on Hormone Therapy

Hot flashes, joint pain and vaginal dryness are common. Aromatase inhibitors can reduce bone density and raise fracture risk, so your team may check bone health. Tamoxifen raises the risk of blood clots and can affect the womb lining, so report unexpected vaginal bleeding to your doctor promptly.

Blood, Liver and Heart Checks on Targeted Drugs

• Blood counts are monitored with CDK4/6 and PARP inhibitors, which can cause low white cells (neutropenia) or anemia.
• Liver tests are used with some targeted drugs, including ribociclib.
• Blood sugar is checked with PI3K and AKT pathway medicines, which can raise it.
• An ECG may be used with ribociclib, which can lengthen the QT interval, a measure of the heart’s electrical rhythm.

When the Cancer Progresses on Treatment

Cancer cells can change and stop responding. Progression means the current medicine no longer controls the disease well enough, not that options have run out. Depending on the situation, your team may retest the cancer with a repeat biopsy or a blood test for tumor DNA. This is not needed every time. The next treatment depends on the cancer’s features, earlier treatment and new results.

Key Takeaways

• Testing shows which treatments may suit your tumor.
• Hormone therapy is central to treating hormone receptor positive cancer.
• Treatment length, checks and later options depend on your cancer’s stage and biology.